Qiagen

Verogen, Inc. is an independent forensic genomics company based in San Diego, California, that specializes in next-generation sequencing solutions tailored for law enforcement, criminal justice, and national security organizations. Founded in 2017, Verogen offers the MiSeq FGx forensic genomics solution, which enables the analysis of forensically relevant genetic markers in a single interrogation while automating cluster generation and eliminating sequencing errors. The company also provides ForenSeq universal analysis software, which aids in visualizing short tandem repeat (STR) and single nucleotide polymorphism (SNP) data, ensuring sample quality, and estimating ancestry, phenotype, and profile frequency statistically. By developing DNA-based biometric identification products, Verogen supports forensic laboratories and the global human identification community in resolving criminal cases and locating missing persons.

BLIRT S.A. is a biotechnology company based in Gdansk, Poland, established in 2008. It specializes in the production of specialty enzymes and proteins used in nucleic acid purification and sequencing. The company develops and commercializes both standardized and customized solutions for proteins and enzymes, catering to the life sciences and diagnostic kit industries. BLIRT's product offerings include a range of protein products such as proteinases, RNase inhibitors, reverse transcriptases, polymerases, nucleases, ligases, and recombinant proteins. Additionally, the company provides molecular biology reagents, including DNA and RNA extraction kits, PCR and real-time PCR solutions, reverse transcription products, and electrophoresis tools. BLIRT also engages in research and development activities and offers contract services in biotechnology, microbiology, chemical synthesis, and analytics.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Actome specializes in emulsion coupling technology and interactome technology to advance life science research and personalized medicine. The company has developed a proprietary method that allows for the detection of single protein molecules and protein interaction complexes. By translating protein status into DNA barcodes using DNA-labeled antibodies, Actome enables detailed molecular biological research. This innovative approach aids clients in quantifying proteins, analyzing protein interactions, and studying post-translational modifications in biological samples. Through its technologies, Actome contributes to advancements in pharmaceuticals and the development of novel personalized therapies.

Verogen, Inc. is an independent forensic genomics company based in San Diego, California, that specializes in next-generation sequencing solutions tailored for law enforcement, criminal justice, and national security organizations. Founded in 2017, Verogen offers the MiSeq FGx forensic genomics solution, which enables the analysis of forensically relevant genetic markers in a single interrogation while automating cluster generation and eliminating sequencing errors. The company also provides ForenSeq universal analysis software, which aids in visualizing short tandem repeat (STR) and single nucleotide polymorphism (SNP) data, ensuring sample quality, and estimating ancestry, phenotype, and profile frequency statistically. By developing DNA-based biometric identification products, Verogen supports forensic laboratories and the global human identification community in resolving criminal cases and locating missing persons.

NeuMoDx Molecular, Inc. is a molecular diagnostics company based in Ann Arbor, Michigan, founded in 2012. It specializes in developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. The company’s platform provides in-vitro testing tools that enhance the efficiency and cost-effectiveness of laboratory operations. By improving the capabilities of laboratory professionals, NeuMoDx aims to increase the adoption of molecular diagnostic testing among medical providers, facilitating earlier and more accurate disease identification and treatment. In 2013, NeuMoDx changed its name from Molecular Systems Corporation and has since become a subsidiary of QIAGEN N.V.

N-of-One, Inc. is a molecular decision support company that specializes in the interpretation of molecular test results for cancer care. It provides clinicians with detailed insights into the biological relevance of diseases, clinical evidence, associated therapies, and references. The company interprets next-generation sequencing (NGS) data from solid and hematological tumors, as well as circulating tumor cells and DNA. N-of-One delivers a clinical interpretation report called PrecisionInsights, which covers 15-20 gene NGS panels, summarizing clinical and scientific evidence for each biomarker relevant to specific cancer subtypes and listing potential therapeutic options. Additionally, it offers TRIALMATCH, a solution for matching patients to suitable clinical trials based on their individual profiles. N-of-One serves various stakeholders, including commercial and hospital laboratories and precision medicine programs. Founded in 2007 and based in Lexington, Massachusetts, N-of-One operates as a subsidiary of QIAGEN N.V. since January 2019.

Parsagen Diagnostics is comprised of a team of passionate and driven leaders who have a proven ability to bring a product from conception through commercialization in multiple global markets. As they expand their presence in the US & abroad, they are looking for people who exhibit flexibility under pressure, who have a proclivity to seek & approach challenges with optimism and grit, and who can identify areas of need and contribute to their ultimate fulfillment.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

OmicSoft Corporation specializes in bioinformatics software for managing, visualizing, and analyzing biomarker data, primarily serving pharmaceutical and biotech companies, universities, hospitals, and research institutes globally. Founded in 2007 and headquartered in Cary, North Carolina, the company offers a suite of tools including Array Suite for NGS data processing, Genetic Variant Annotation for data annotation, and various 'Land' platforms (CVMLand, ImmunoLand, OncoLand, DiseaseLand) for exploring public and private genomics datasets. Additionally, OmicSoft provides data analysis services, custom installation services, and the GeneticsLand solution for big genetic data storage and visualization. Since 2017, OmicSoft has operated as a subsidiary of QIAGEN N.V.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

MO BIO Laboratories, Inc. specializes in DNA and RNA isolation and protein extraction tools, focusing on the development and manufacture of innovative products for life science research. The company provides a range of services, including soil, stool, and microbial nucleic acid purification, as well as certifications and sterility assurance for various plastic and medical device suppliers. Additionally, MO BIO Laboratories offers sterility assurance kits to ensure the quality of water and food products. Founded in 1993 and located in Carlsbad, California, the company distributes its products through various channels in the United States and internationally. As of November 2015, it operates as a subsidiary of Qiagen NV.

Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

BIOBASE is a provider of expert-curated biological databases, software and services for the life sciences.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

CLC bio is a prominent provider of bioinformatics solutions, specializing in the analysis of genomic data derived from various high-throughput sequencing technologies. The company focuses on software development for both next-generation sequencing platforms and traditional Sanger-based sequencing methods. By offering enterprise software tailored to the needs of researchers and organizations in the genomics field, CLC bio supports the advancement of genetic research and data interpretation across a range of applications.

Ingenuity Systems is a software platform designed to support life science researchers by providing access to crucial information services. The platform allows enterprise customers to facilitate the use of internal portals, search engines, and various software tools, enabling researchers to efficiently search, explore, visualize, and analyze biological and chemical data related to genes, proteins, and small molecules. By streamlining access to these resources, Ingenuity Systems enhances the research capabilities of its users, ultimately contributing to advancements in the life sciences field.

Drug Response Dx, headquartered in Hennigsdorf, Germany, was founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis. Their tests utilize a protein that predicts the individual effectiveness of TNF-alpha inhibitors, allowing for personalized treatment planning prior to medication administration. This approach facilitates timely initiation of treatment and increases the likelihood of positive patient outcomes. The company's biomarker set is prevalidated, and they have established proof of concept using serum samples from rheumatoid arthritis patients.

Intelligent Bio-Systems, founded in 2005 by Drs. Steven J. Gordon and Jingyue Ju, focuses on the commercialization of advanced DNA sequencing systems. The company aims to enhance the speed and reduce the cost of generating sequence data, making its technology applicable in various fields, including research, clinical applications, and DNA resequencing. Its systems are particularly valuable for cancer and HIV/AIDS applications, allowing customers to achieve low-cost throughput sequencing while ensuring high-quality data. Dr. Gordon's background includes founding Intelligent Automation Systems, which contributed significantly to the Human Genome Project, while Dr. Ju is noted for her pioneering work on fluorescent energy transfer dyes that are integral to many electrophoresis-based sequencing technologies.

AmniSure International specializes in the development and marketing of the AmniSure diagnostic test, designed to detect rupture of fetal membranes (ROM) in pregnant women. The test, which has received FDA clearance and is approved for use in various international markets, utilizes proprietary technology to identify small amounts of amniotic fluid in vaginal discharge. This one-step, minimally invasive test provides results in just minutes at the point of care, boasting an accuracy rate near 99%, significantly surpassing traditional testing methods. AmniSure is recognized as a gold-standard test in pregnancy care and is reimbursable under most U.S. state Medicaid plans, making it an essential tool for healthcare professionals in managing pregnancy complications.

Xagenic Inc. is a Toronto-based molecular diagnostics company focused on developing innovative technology for decentralized and rapid diagnostic testing. The company aims to enhance patient care by enabling on-demand, near-patient molecular testing, which allows clinicians to make informed treatment decisions during the initial consultation. Xagenic's technology facilitates rapid, enzyme-free detection of nucleic acids from clinical samples, yielding results in just 20 minutes. By commercializing a simple and fully automated platform, Xagenic is positioned to revolutionize diagnostic testing by enabling it to be conducted outside of traditional clinical laboratories. The company is also working on tests for infectious diseases that provide clinically actionable results in a timely manner, thereby improving overall healthcare efficiency and reducing costs.

Cellestis is manufactures and markets QuantiFERON products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses using whole blood samples.

Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.

ESE GmbH is a company that was acquired by Qiagen in 2010.

SABiosciences Corporation, established in 1998, is a privately held biotechnology company that specializes in developing research tools for biological studies. The company focuses on creating disease and pathway-specific real-time PCR-based assay panels, which combine hypothesis-driven and discovery-based research methodologies. By providing innovative solutions, SABiosciences aims to enhance the efficiency and effectiveness of biological research in the post-genomic era.

DxS (now a Qiagen company) is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, DxS will support the development and sales of targeted cancer therapies by providing companion diagnostic products and services. Since its founding in 2001, DxS has experienced considerable growth and firmly established itself as a leader in companion diagnostics, having recently secured deals with leading healthcare companies such as Amgen, Boehringer Ingelheim, and AstraZeneca. In addition, DxS has an exclusive agreement with Roche Diagnostics for the global distribution of its diagnostic products. DxS has a portfolio of cancer mutation products including both diagnostic and assays for research use. The TheraScreen® range of CE-marked (IVD) diagnostic* kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS currently produce two diagnostic kits, TheraScreen K-RAS and TheraScreen EGFR29. The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS was acquired by Qiagen (NASDQ : QGEN) and continues to operate from the heart of Manchester’s Technology Quarter in the UK.

Explera s.r.l. is a company that specializes in the import, manufacture, and marketing of products for molecular biology research laboratories, both in Italy and internationally. The company provides a range of laboratory instruments, including DNA sequencing equipment, thermal cyclers, ultra-compact thermal cycling devices, and photo-documentation systems. Additionally, Explera offers various small laboratory tools such as shakers, rotators, multi shakers, shakers-incubators, centrifuges, vortexes, thermostats, water baths, dry blocks, and magnetic stirrers, as well as biohazard and PCR cabinets. Through its diverse product offerings, Explera supports the needs of research and medical laboratories in advancing molecular biology studies.

Corbett Life Science Pty., Ltd. designs, manufactures, and distributes instrumentation systems for the life sciences sector on an international scale. The company is known for its innovative products, including the Rotor-Gene, a real-time PCR cycler, and a range of automation solutions such as the CAS-1200 PCR setup robot and precision liquid handling workstations like the CAS-4200 and CAS-4800. Additionally, Corbett offers the X-tractor Gene nucleic acid extraction system, the Palm-Cycler thermal cycler, and various reagents and software tools for DNA analysis. Its products facilitate critical processes like DNA amplification, extraction, and analysis, serving laboratories worldwide, including regions such as North America, Europe, and Asia. Founded in 1988 and headquartered in Sydney, Australia, Corbett Life Science operates additional units in Brisbane, the United Kingdom, and the United States. The company has a strategic partnership with Sigma-Aldrich and has been a subsidiary of Qiagen NV since 2008.

eGene, Inc. is a biotechnology company, engages in developing, manufacturing, and marketing analytical systems and reagents for the genotyping market. It uses capillary electrophoresis, microfluidics, reagents liquid handling, and automation technologies to create a DNA/RNA analysis system for biological materials and life sciences testing. The company offers HDA-GT12 genetic analyzer, which uses capillary electrophoresis-based technology for DNA/RNA separation. Its HDA-GT12 system is used to detect, quantify, identify, and characterize biological organisms, as well as to automate the routine and non-routine laboratory and industrial procedures.

Digene Corporation is develops, manufactures, and markets proprietary gene-based diagnostic tests for the screening, monitoring, and diagnosis of human diseases with a focus on women’s cancers and infectious diseases worldwide. The company primarily offers human papillomavirus (HPV) testing products, which are FDA-approved tests for the detection of HPV, are a reproducible, objective test for the primary cause of cervical cancer. Its primary product is The Digene HPV Test, a FDA-approved test for HPV, the primary cause of cervical cancer.

Genaco Biomedical Products, Inc. develops and markets medical genetic products and services in China. The company offers prenatal screening; neonatal screening; commercial kits for prenatal screening and diagnosis of common genetic diseases; cytogenetic equipment; molecular genetics equipment, such as gel boxes and power supplies; and general laboratory supplies. It distributes its products through distributors and medical genetic centers.

Gentra Systems, Inc. develops and markets nucleic acid purification reagents and instruments for clinical and clinical research laboratories. The company’s DNA and RNA purification products include Generation Kits, which provide DNA purification for small samples; Purescript kit that provides a non-toxic method for purifying RNA; Autopure ls instrument for processing samples, by purifying Puregene-quality DNA from blood samples; and Versagene RNA.

Shenzhen PG Biotech Co, Ltd., is a molecular biology company, engages in the development, manufacture, and marketing of research and clinic diagnosis reagents and instruments. Its integrated services include technical consultation, product introduction, and customer order upon request, as well as after-sale service. The company serves in the areas of scientific fields, including molecular biology, cell biology, genetics, microbiology, and management.

Nextal Biotechnologies, located in Holland, Ohio, focuses on producing screens and plates essential for protein crystallization, a critical component in structural biology and structure-based drug design. The company's products cater to the experimental requirements of crystallization by offering innovative plates that feature grease-free, independent screwable supports. As of January 2020, Nextal Biotechnologies operates as a subsidiary of CalibreScientific Inc.

Artus GmbH is a biotechnology company that specializes in the development, production, and sale of diagnostic kits utilizing advanced DNA analytical techniques. The company primarily focuses on polymerase chain reaction (PCR) and real-time PCR technologies to detect infectious agents. Its diagnostic kits are employed across various fields, including pharmacogenomics and veterinary diagnostics, helping users achieve more accurate and effective diagnoses.

Molecular Staging, Inc. is a life sciences tool company focused on developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings encompass various applications in proteomics, genomics, pharmacogenomics, and diagnostics. Notable products include protein microarrays, which allow researchers to analyze multiple proteins simultaneously, and whole-genome amplification technology that addresses challenges posed by limited DNA sample quantities. Additionally, the company provides multiplexed diagnostics, facilitating the earlier detection of diseases and enhancing confirmatory diagnoses. Through these innovations, Molecular Staging supports advancements in research and clinical applications.

Xeragon is develops and markets products and services focusing on oligoribonucleotides (RNA). The company’s TOM-Amidite technology allows chemical synthesis of RNA and its siRNA technology helps in RNA synthesis and gene silencing. Xeragon’s products and services are used by RNA scientists in the fields of biopharmaceuticals, diagnostics, therapeutics, and structural studies.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.